Vaxcyte (PCVX) Price & Analysis

Compare

433 Followers

PCVX Stock Chart & Stats

$44.59

-$2.14(-2.45%)

At close: Jan 08 4:00 PM EST

$44.59

-$2.14(-2.45%)

Day’s Range― - ―

52-Week Range$27.66 - $93.77

Previous CloseN/A

Volume105.48K

Average Volume (3M)1.43M

Market Cap

$5.86B

Enterprise Value$3.28B

Total Cash (Recent Filing)$1.71B

Total Debt (Recent Filing)$84.44M

Price to Earnings (P/E)―

Beta1.61

Next Earnings

Mar 02, 2026

EPS Estimate

-1.5

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.56

Shares Outstanding130,906,270

10 Day Avg. Volume1,362,822

30 Day Avg. Volume1,427,943

Financial Highlights & Ratios

PEG Ratio2.62

Price to Book (P/B)3.02

Price to Sales (P/S)0.00

P/FCF Ratio-21.02

Enterprise Value/Market Cap0.56

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-657.23

Enterprise Value/Ebitda-5.47

Forecast

1Y Price Target

$100.80

Price Target Upside126.06% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

EPS Forecast (FY)-5.41

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Cash ReservesPCVX ended the quarter with $2.7B in cash and investments, which is expected to provide runway to 2028.

Market AdvantageThis increased margin for success should help hinder future competitors once VAX-31 is an established vaccine.

Vaccine ApprovalThe approval of VAX-31 in adults will be based on immunogenicity for the covered serotypes as has been the case for PCVs since the earliest readouts.

Bears Say

Vaccine PerformanceVAX-31 will fail to be non-inferior to PCV20 for 2-4 serotypes, although it provides similar protection to 75% of children.

Vaxcyte News

Vaxcyte announces first participants dosed in OPUS Phase 3 trial of VAX-31

Vaxcyte (PCVX) announced that the first participants were dosed in the OPUS Phase 3 pivotal, noninferiority trial evaluating...

5d ago

PCVX

Promising Potential of Vaxcyte’s VAX-31 Vaccine Drives Buy Rating

BTIG analyst Thomas Shrader has maintained their bullish stance on PCVX stock, giving a Buy rating on December...

3d ago

PCVX

Vaxcyte’s Strategic Phase 3 Trial Initiation and Its Market Implications

In a report released today, Joseph Stringer from Needham maintained a Buy rating on Vaxcyte, with a price...

5d ago

PCVX

Vaxcyte, Inc. Reports Q3 2025 Financial Results

Vaxcyte, Inc. ( ($PCVX) ) has released its Q3 earnings. Here is a breakdown of the information Vaxcyte,...

1M ago

PCVX

Promising Vaccine Trials and Undervaluation Drive Buy Rating for Vaxcyte

Analyst Tara Bancroft of TD Cowen maintained a Buy rating on Vaxcyte, retaining the price target of $50.00....

1M ago

PCVX

Vaxcyte reports Q3 EPS ($1.56), consensus ($1.25)

Cash, cash equivalents and investments were $2.67B as of September 30, 2025, compared to $3.135B as of December...

1M ago

PCVX

Vaxcyte’s VAX-31 Study: A Potential Game-Changer in Infant Vaccination

Vaxcyte, Inc. (($PCVX)) announced an update on their ongoing clinical study. Vaxcyte, Inc. is conducting a Phase 2...

2M ago

PCVX

Vaxcyte price target lowered to $85 from $160 at BTIG

BTIG analyst Thomas Shrader lowered the firm’s price target on Vaxcyte (PCVX) to $85 from $160 and keeps...

2M ago

PCVX

Vaxcyte Signs 15-Year Agreement with Patheon

An update from Vaxcyte ( ($PCVX) ) is now available. On September 24, 2025, Vaxcyte, Inc. entered into...

2M ago

PCVX

Vaxcyte to establish fill-finish manufacturing in North Carolina

Vaxcyte (PCVX) announced a new agreement with Thermo Fisher Scientific (TMO) to bring additional fill-finish commercial manufacturing for...

2M ago

TMO

PCVX

Vaxcyte initiated with a Neutral at Goldman Sachs

Goldman Sachs initiated coverage of Vaxcyte (PCVX) with a Neutral rating and $38 price target The firm believes...

3M ago

PCVX

Vaxcyte advances VAX-31 infant Phase 2 study

Vaxcyte (PCVX) announced advancement of the modified VAX-31 infant Phase 2 randomized, dose-finding study to the third and...

3M ago

PCVX

Vaxcyte Reports Progress in Vaccine Development

Vaxcyte, Inc. ( ($PCVX) ) has released its Q2 earnings. Here is a breakdown of the information Vaxcyte,...

4M ago

PCVX

Vaxcyte’s Strategic Advancements and Financial Stability Justify Buy Rating

Leerink Partners analyst David Risinger has maintained their bullish stance on PCVX stock, giving a Buy rating yesterday....

4M ago

PCVX

PCVX FAQ

What was Vaxcyte, Inc.’s price range in the past 12 months?

Vaxcyte, Inc. lowest stock price was $27.66 and its highest was $93.77 in the past 12 months.

What is Vaxcyte, Inc.’s market cap?

Vaxcyte, Inc.’s market cap is $5.86B.

When is Vaxcyte, Inc.’s upcoming earnings report date?

Vaxcyte, Inc.’s upcoming earnings report date is Mar 02, 2026 which is in 79 days.

How were Vaxcyte, Inc.’s earnings last quarter?

Vaxcyte, Inc. released its earnings results on Nov 04, 2025. The company reported -$1.56 earnings per share for the quarter, missing the consensus estimate of -$1.238 by -$0.322.

Is Vaxcyte, Inc. overvalued?

According to Wall Street analysts Vaxcyte, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Vaxcyte, Inc. pay dividends?

Vaxcyte, Inc. does not currently pay dividends.

What is Vaxcyte, Inc.’s EPS estimate?

Vaxcyte, Inc.’s EPS estimate is -1.5.

How many shares outstanding does Vaxcyte, Inc. have?

Vaxcyte, Inc. has 130,906,270 shares outstanding.

What happened to Vaxcyte, Inc.’s price movement after its last earnings report?

Vaxcyte, Inc. reported an EPS of -$1.56 in its last earnings report, missing expectations of -$1.238. Following the earnings report the stock price went down -2.491%.

Which hedge fund is a major shareholder of Vaxcyte, Inc.?

Currently, no hedge funds are holding shares in PCVX

Vaxcyte Stock Smart Score

Neutral

Fundamentals

Return on Equity

-20.83%

Trailing 12-Months

Asset Growth

-10.90%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Vaxcyte, Inc.

Vaxcyte, Inc. (PCVX) is a biotechnology company focused on developing innovative vaccines for the prevention of infectious diseases. Operating within the pharmaceutical and biotechnology sectors, Vaxcyte's core product offerings include conjugate and protein-based vaccines designed to address significant unmet medical needs. The company's lead vaccine candidates aim to provide comprehensive protection against pneumococcal infections and other bacterial pathogens.

Vaxcyte (PCVX) Earnings & Revenues

Historic Earnings Reports

PCVX Stock 12 Month Forecast

Average Price Target

$100.80

▲(126.06% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"30":"$30","97":"$97","164":"$164","63.5":"$63.5","130.5":"$130.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":163,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$163.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":100.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$100.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$50.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[30,63.5,97,130.5,164],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,45.52,54.55692307692308,63.59384615384616,72.63076923076923,81.6676923076923,90.70461538461538,99.74153846153845,108.77846153846153,117.8153846153846,126.85230769230768,135.88923076923075,144.92615384615382,153.96307692307693,{"y":163,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,45.52,49.77230769230769,54.02461538461539,58.27692307692308,62.52923076923077,66.78153846153846,71.03384615384616,75.28615384615385,79.53846153846155,83.79076923076923,88.04307692307692,92.29538461538462,96.5476923076923,{"y":100.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,45.52,45.86461538461539,46.20923076923077,46.55384615384616,46.89846153846154,47.24307692307693,47.58769230769231,47.932307692307695,48.276923076923076,48.621538461538464,48.966153846153844,49.31076923076923,49.65538461538462,{"y":50,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":107.29,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.6,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.86,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.32,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.02,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.23,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.24,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.02,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.02,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.56,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.03,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.28,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.52,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >